Literature DB >> 3401247

Distribution and metabolism of estramustine in HeLa cells and the human prostatic tumour cell line 1013L.

E Kruse1, S A Johansson, B Hartley-Asp, P O Gunnarsson.   

Abstract

The metabolism of estramustine [estradiol-3-N-bis(2-chloroethyl) carbamate] was investigated in the human prostatic tumour cell line 1013L and the human cervix tumour cell line HeLa S3. Uptake studies revealed that estramustine (EM), and its 17-ketoanalogue estromustine (EoM), differed in their nuclear binding pattern in 1013L cells but not in HeLa cells. Most of the nuclear radioactivity from both EM and EoM was found in the fraction containing the majority of the phospholipids. HPLC studies on EM-treated 1013L cells showed the presence of the oxidized metabolite EoM, in the medium, an enrichment of estradiol and estrone in whole cells and EM and EoM bound to the nuclear protein matrix. Similar studies on the HeLa cell line showed a completely different pattern, no metabolites other than EoM were found in the cell medium and whole cells but several very lipophilic metabolites were found bound to the nuclear protein matrix. On investigation of other tumour cell lines these metabolites were found to be unique to HeLa cells. The results extend our knowledge concerning EM and demonstrate that the cell line 1013L is a relevant model system for studying drugs active against human prostatic tumours.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3401247     DOI: 10.1016/0006-2952(88)90315-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Presence of oestrogen receptors on target cells and antiproliferative activity of estramustine phosphate: positive correlation for human tumours in vitro.

Authors:  J Pavelić; I Zgradić; K Pavelić
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

Review 2.  Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  C M Perry; D McTavish
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

3.  Plasma osteocalcin values and related hormonal parameters in patients subjected to a variety of prostate anticancer agents.

Authors:  M Tarle
Journal:  Urol Res       Date:  1991

4.  Accumulation of estramustine and estromustine in adipose tissue of rats and humans.

Authors:  P O Gunnarsson; S B Andersson; A A Sandberg; M Ellman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

5.  Growth inhibiting effect of estramustine on two prostatic carcinoma cell lines, LNCaP and LNCaP-r.

Authors:  M Hansenson; B Lundh; B Hartley-Asp; A Pousette
Journal:  Urol Res       Date:  1988

6.  Uptake and retention of estramustine and the presence of estramustine binding protein in malignant brain tumours in humans.

Authors:  A T Bergenheim; P O Gunnarsson; K Edman; E von Schoultz; M I Hariz; R Henriksson
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.